Targeting Pathways in Neuroblastoma: Advances in Treatment Strategies and Clinical Outcomes
Diana Benchia, Ovidiu Bîcă, Ioan Sârbu, Bogdan Savu, Diana Farcaș, Ingrith Miron, Anca Lavinia Cianga, Elena Cojocaru, Olivier Abbo, Carmen Iulia Ciongradi
Abstract
Neuroblastoma (NB) is a childhood cancer originating from neural crest cells of the sympathetic nervous system. Despite the advances in multimodal therapy, the treatment of high-risk NB remains challenging. The present review outlines several evidence-related insights into the molecular mechanisms of NB pathogenesis, focusing on genetic drivers (e.g., MYCN amplification) and disrupted signaling pathways (PI3K/Akt/mTOR; Notch; Jak2/STAT3), as well as on the tumor microenvironment's role in progression and resistance. The authors highlight current and emerging therapeutic strategies, including molecularly targeted agents; immunotherapies; and differentiation approaches under investigation. The complexity and heterogeneity of NB underscores the need for continued translational research and for combined strategies aimed at improving outcomes for affected children, highlighting the need for integration of molecular profiling and precision medicine to guide treatment.